Rafferty Asset Management
VERA icon

Rafferty Asset Management’s Vera Therapeutics VERA Stock Holding History

Rafferty Asset Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Sell
73,469
-28,317
-28% -$1.06M 0.01% 530
2026
Q1 		$4.09M Buy
101,786
+15,950
+19% +$687K 0.02% 456
2025
Q4 		$4.35M Sell
85,836
-1,661
-2% -$59K 0.02% 468
2025
Q3 		$2.54M Buy
87,497
+15,429
+21% +$357K 0.01% 588
2025
Q2 		$1.7M Sell
72,068
-12,808
-15% -$288K 0.01% 645
2025
Q1 		$2.04M Sell
84,876
-2,810
-3% -$90.3K 0.01% 576
2024
Q4 		$3.71M Buy
87,686
+8,741
+11% +$387K 0.01% 472
2024
Q3 		$3.49M Sell
78,945
-42,811
-35% -$1.62M 0.01% 492
2024
Q2 		$4.41M Sell
121,756
-53,027
-30% -$2.1M 0.02% 448
2024
Q1 		$7.54M Buy
174,783
+4,025
+2% +$143K 0.03% 362
2023
Q4 		$2.63M Buy
170,758
+34,381
+25% +$437K 0.01% 602
2023
Q3 		$1.87M Buy
+136,377
New +$2.34M 0.01% 627

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Rafferty Asset Management's VERA Position: Q2 2026 in Review

Rafferty Asset Management reduced its Vera Therapeutics (VERA) stake by 28% in Q2 2026, selling an estimated $1.06M and leaving 73,469 shares worth $3.15M. The position accounts for 0.01% of the portfolio, ranked #530.

Rafferty Asset Management first reported a position in VERA in Q3 2023 and has held it in 12 quarters since. The position peaked at $7.54M in Q1 2024. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Rafferty Asset Management held 73,469 shares of Vera Therapeutics worth $3.15M as of Q2 2026.
  • Rafferty Asset Management sold 28,317 Vera Therapeutics shares in Q2 2026, an estimated $1.06M.
  • Vera Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #530 holding.
  • Rafferty Asset Management first reported a position in Vera Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Rafferty Asset Management's Vera Therapeutics position peaked at $7.54M in Q1 2024.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.